Ubretid

Cat. No.: HY-119577

CAS No.: 15876-67-2

Molecular Formula: $C_{22}H_{32}Br_2N_4O_4$

Molecular Weight: 576.32

Target: Cholinesterase (ChE)

Pathway: Neuronal Signaling

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (173.51 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.7351 mL	8.6757 mL	17.3515 mL
	5 mM	0.3470 mL	1.7351 mL	3.4703 mL
	10 mM	0.1735 mL	0.8676 mL	1.7351 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder[1].

REFERENCES

[1]. Isono S, et al. Ubretid (distigmine bromide) taken to treat urinary retention prolongs the effect of suxamethonium. J Anesth. 2008;22(3):337.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA